Keros Therapeutics Inc (KROS) concluded trading on Thursday at a closing price of $18.43, with 14.61 million shares of worth about $269.25 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -62.77% during that period and on December 12, 2024 the price saw a loss of about -73.15%. Currently the company’s common shares owned by public are about 39.26M shares, out of which, 30.20M shares are available for trading.
Stock saw a price change of -71.48% in past 5 days and over the past one month there was a price change of -71.59%. Year-to-date (YTD), KROS shares are showing a performance of -53.65% which decreased to -37.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $27.31 but also hit the highest price of $73.00 during that period. The average intraday trading volume for Keros Therapeutics Inc shares is 389.93K. The stock is currently trading -68.24% below its 20-day simple moving average (SMA20), while that difference is down -69.27% for SMA50 and it goes to -66.71% lower than SMA200.
Keros Therapeutics Inc (NASDAQ: KROS) currently have 39.26M outstanding shares and institutions hold larger chunk of about 79.02% of that.
The stock has a current market capitalization of $746.55M and its 3Y-monthly beta is at 1.20. It has posted earnings per share of -$5.21 in the same period. It has Quick Ratio of 19.03 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KROS, volatility over the week remained 9.71% while standing at 6.81% over the month.
Stock’s fiscal year EPS is expected to drop by -0.06% while it is estimated to decrease by -2.98% in next year. EPS is likely to grow at an annualized rate of 4.80% for next 5-years, compared to annual growth of -111.11% made by the stock over the past 5-years.
Stock get an Overweight rating from Cantor Fitzgerald on October 24, 2024.
